Skip to content
type1.science
Phase 2RecruitingNCT07224321

INHALE-1st: Afrezza for youth with newly diagnosed T1D

MannKind phase 2 single-arm study of Afrezza (Technosphere insulin) plus basal insulin in children and adolescents aged 6 to under 18 with newly diagnosed stage 3 type 1 diabetes.

Primary endpoints

  • Percentage of participants with CGM-measured time-in-range at least 70% at 13 weeks

Results so far

No results posted. Recruiting; estimated n=100; started 4 February 2026; estimated primary completion March 2027. Live registry ages are 6 to under 18 (was written as 10 to under 18). Last update 13 August 2026.